Drug Affordability Unit
Frequently Asked Questions
Page Content
-
What is a Reporting Entity?
“Reporting Entity” means any manufacturer, carrier, pharmacy benefits manager, wholesaler, pharmacy services administrative organization, or any other entity required to report to the Division under P.L.2023, c.106. See N.J.S.A. 45:82.2.
-
When will Reporting Entities start to register with the Drug Affordability Unit?
Registration of Reporting Entities under P.L. 2023, c. 106 will begin in January 2025. Reporting Entities will register on an annual basis by January 31 of each calendar year. See N.J.S.A. 45:14-82.9.
-
When will notifications and reporting by manufacturers begin?
The price increase and new drug notification and reporting requirements of P.L. 2023, c. 106 (codified at N.J.S.A. 45:14-82.3) took effect on August 1, 2024. Manufacturers are expected to comply with those statutory requirements, even if the price increase or introduction of a new drug occurred prior to the publication of regulations implementing P.L. 2023, c. 106.
-
How can I sign up to get notifications from the Drug Affordability Unit?
Sign up
here to receive notifications from the Drug Affordability Unit.
-
Where may I direct questions about P.L. 2023, c. 106?
Questions can be sent via email to
DAU@dca.njoag.gov.
Last Modified: 10/15/2024 11:23 AM
